Siremadlin
- Generic Name
- Siremadlin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H24Cl2N6O4
- CAS Number
- 1448867-41-1
- Unique Ingredient Identifier
- 0282IF4JC8
- Associated Conditions
- -
- Associated Therapies
- -
Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT05599932
- Locations
- ๐บ๐ธ
Texas Liver Institute, San Antonio, Texas, United States
๐บ๐ธClinical Pharmacology of Miami LLC, Miami, Florida, United States
๐บ๐ธOrlando Clinical Research Center, Orlando, Florida, United States
A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT05447663
- Locations
- ๐ช๐ธ
Novartis Investigative Site, Valencia, Spain
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT05155709
- Locations
- ๐น๐ท
Novartis Investigative Site, Izmir, Turkey
๐บ๐ธOregon Health Sciences University ., Portland, Oregon, United States
๐บ๐ธTexas Oncology Sammons Cancer Center Sammons Cancer Center (SC), Dallas, Texas, United States
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT04097821
- Locations
- ๐ฌ๐ง
Novartis Investigative Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2024. All Rights Reserved by MedPath